223 related articles for article (PubMed ID: 26977024)
1. The Clinical Implications of RSK1-3 in Human Breast Cancer.
Zhao H; Martin TA; Davies EL; Ruge F; Yu H; Zhang Y; Teng XU; Jiang WG
Anticancer Res; 2016 Mar; 36(3):1267-74. PubMed ID: 26977024
[TBL] [Abstract][Full Text] [Related]
2. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
[TBL] [Abstract][Full Text] [Related]
3. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation.
Smith JA; Poteet-Smith CE; Xu Y; Errington TM; Hecht SM; Lannigan DA
Cancer Res; 2005 Feb; 65(3):1027-34. PubMed ID: 15705904
[TBL] [Abstract][Full Text] [Related]
4. Aberrant expression of RSK1 characterizes high-grade gliomas with immune infiltration.
M Hajj GN; da Silva FF; de Bellis B; Lupinacci FCS; Bellato HM; Cruz JR; Segundo CNC; Faquini IV; Torres LC; Sanematsu PI; Begnami MD; Martins VR; Roffé M
Mol Oncol; 2020 Jan; 14(1):159-179. PubMed ID: 31701625
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity.
Roux PP; Richards SA; Blenis J
Mol Cell Biol; 2003 Jul; 23(14):4796-804. PubMed ID: 12832467
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)-ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration.
Yang S; Ji M; Zhang L; Chen Y; Wennmann DO; Kremerskothen J; Dong J
Cell Signal; 2014 Feb; 26(2):343-51. PubMed ID: 24269383
[TBL] [Abstract][Full Text] [Related]
7. Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.
Czaplinska D; Mieczkowski K; Supernat A; Skladanowski AC; Kordek R; Biernat W; Zaczek AJ; Romanska HM; Sadej R
Tumour Biol; 2016 Oct; 37(10):13721-13731. PubMed ID: 27476168
[TBL] [Abstract][Full Text] [Related]
8. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer.
Ludwik KA; Campbell JP; Li M; Li Y; Sandusky ZM; Pasic L; Sowder ME; Brenin DR; Pietenpol JA; O'Doherty GA; Lannigan DA
Mol Cancer Ther; 2016 Nov; 15(11):2598-2608. PubMed ID: 27528706
[TBL] [Abstract][Full Text] [Related]
9. Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner.
Roffé M; Lupinacci FC; Soares LC; Hajj GN; Martins VR
Cell Signal; 2015 Aug; 27(8):1630-42. PubMed ID: 25889895
[TBL] [Abstract][Full Text] [Related]
10. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation.
Clark DE; Errington TM; Smith JA; Frierson HF; Weber MJ; Lannigan DA
Cancer Res; 2005 Apr; 65(8):3108-16. PubMed ID: 15833840
[TBL] [Abstract][Full Text] [Related]
11. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.
Cuesta R; Holz MK
Oncotarget; 2016 May; 7(19):27567-83. PubMed ID: 27028868
[TBL] [Abstract][Full Text] [Related]
12. L-plastin Ser5 phosphorylation in breast cancer cells and in vitro is mediated by RSK downstream of the ERK/MAPK pathway.
Lommel MJ; Trairatphisan P; Gäbler K; Laurini C; Muller A; Kaoma T; Vallar L; Sauter T; Schaffner-Reckinger E
FASEB J; 2016 Mar; 30(3):1218-33. PubMed ID: 26631483
[TBL] [Abstract][Full Text] [Related]
13. [Abnormal expression of RSK-4 and its clinical significance in breast cancer].
Liu JL; Yang HW; Chen ZS; Jiang Y
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):452-6. PubMed ID: 21875487
[TBL] [Abstract][Full Text] [Related]
14. The RSK factors of activating the Ras/MAPK signaling cascade.
Carriere A; Ray H; Blenis J; Roux PP
Front Biosci; 2008 May; 13():4258-75. PubMed ID: 18508509
[TBL] [Abstract][Full Text] [Related]
15. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
[TBL] [Abstract][Full Text] [Related]
16. Ribosomal protein S6 kinase (RSK)-2 as a central effector molecule in RON receptor tyrosine kinase mediated epithelial to mesenchymal transition induced by macrophage-stimulating protein.
Ma Q; Guin S; Padhye SS; Zhou YQ; Zhang RW; Wang MH
Mol Cancer; 2011 May; 10():66. PubMed ID: 21619683
[TBL] [Abstract][Full Text] [Related]
17. Influence of rhamnose substituents on the potency of SL0101, an inhibitor of the Ser/Thr kinase, RSK.
Smith JA; Maloney DJ; Clark DE; Xu Y; Hecht SM; Lannigan DA
Bioorg Med Chem; 2006 Sep; 14(17):6034-42. PubMed ID: 16723233
[TBL] [Abstract][Full Text] [Related]
18. Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.
Stratford AL; Reipas K; Hu K; Fotovati A; Brough R; Frankum J; Takhar M; Watson P; Ashworth A; Lord CJ; Lasham A; Print CG; Dunn SE
Stem Cells; 2012 Jul; 30(7):1338-48. PubMed ID: 22674792
[TBL] [Abstract][Full Text] [Related]
19. Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism.
Torchiaro E; Lorenzato A; Olivero M; Valdembri D; Gagliardi PA; Gai M; Erriquez J; Serini G; Di Renzo MF
Oncotarget; 2016 Jan; 7(1):712-28. PubMed ID: 26625210
[TBL] [Abstract][Full Text] [Related]
20. Regulation and function of the RSK family of protein kinases.
Romeo Y; Zhang X; Roux PP
Biochem J; 2012 Jan; 441(2):553-69. PubMed ID: 22187936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
